Dynavax Announces Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Dynavax (DVAX) Tops Q4 EPS by 10c
February 25, 2021 5:27 PM ESTDynavax (NASDAQ: DVAX) reported Q4 EPS of ($0.14), $0.10 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $19.55 million versus the consensus estimate of $13.06 million.
"2020 was an important year for Dynavax as we continue to build a leading vaccine company underpinned... More
